MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s13555-025-01362-w

Медицинская библиотека · Dermatology and therapy · 2025

Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials.

Armstrong April W, Kircik Leon, Stein Gold Linda, Strober Bruce, De Oliveira Claudia H M C, Vaile John, Jou Ying-Ming, Daamen Carolin, Scharnitz Thomas, Lebwohl Mark

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the USA and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. In POETYK PSO-1 and PSO-2, deucravacitinib was superior to placebo and apremilast and well tolerated in patients with plaque psoriasis. Patients who completed PSO-1/PSO-2 could enroll in the POETYK long-term extension (LTE) trial. This analysis evaluates the effects of deucravacitinib on laboratory parameters.

METHODS

POETYK PSO-1 and PSO-2 were 52-week, phase 3, double-blinded trials that randomized patients 1:2:1 to placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. At week 52, eligible patients enrolled in POETYK LTE and received open-label deucravacitinib. Mean changes from baseline in laboratory parameters, laboratory adverse events (AEs), and laboratory AEs resulting in discontinuation were evaluated over 3 years.

RESULTS

A total of 1519 patients received one or more doses of deucravacitinib across trials. Total exposure over 3 years was 3294.3 person-years. No clinically relevant mean changes were observed in laboratory parameters. Grade ≥ 3 laboratory AEs were infrequent during the 1-year period, with incidence rates remaining stable in patients treated with deucravacitinib through 3 years. Most laboratory AEs remained at the same grade; shifts to higher grades were infrequent, with most increases being to grade ≤ 2. Discontinuations due to laboratory AEs were rare.

CONCLUSIONS

Deucravacitinib did not result in clinically meaningful changes in laboratory parameters over 3 years, including changes seen with Janus kinase (JAK) 1,2,3 inhibitors. Grade ≥ 3 laboratory AEs and discontinuations were rare.

TRIAL REGISTRATION: ClinicalTrials.gov identifier, POETYK PSO-1 (NCT03624127), POETYK PSO-2 (NCT03611751), POETYK LTE (NCT04036435).

Для цитирования: Armstrong April W, Kircik Leon, Stein Gold Linda, Strober Bruce, De Oliveira Claudia H M C, Vaile John, Jou Ying-Ming, Daamen Carolin, Scharnitz Thomas, Lebwohl Mark. Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials.. Dermatology and therapy. 2025. DOI: 10.1007/s13555-025-01362-w.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.